Traditionally, depression has been positioned as a disorder of serotonin, dopamine, and norepinephrine signaling in the brain [1,2]. Although these neurotransmitter systems are undoubtedly important, modern neuroscience is increasingly recognizing depression as a disorder involving broader neural circuit dysfunction.
One emerging concept is the role of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. Rather than acting as a simple "calming chemical," GABA serves as a key regulator of neural stability, balancing excitation and preventing excessive neuronal activity.
Over the past two decades, substantial evidence has shown reduced GABA concentrations in people with major depressive disorder (MDD), as well as abnormalities in GABA receptor signaling and GABA-producing interneurons [3]. These alterations suggest that impaired inhibitory tone may contribute to depression by disrupting the balance between excitatory and inhibitory neural signaling [3].
The consequences of diminished GABA activity may extend beyond mood regulation. Reduced inhibitory control can amplify stress responses, alter emotional processing, impair cognition, and create a state of neural overload.
This article explores how GABA deficiency may contribute to depression, focusing specifically on excitatory/inhibitory imbalance and stress-related mechanisms of action.
How GABA Works: The Brain’s Braking System
Neurons communicate through chemical messengers called neurotransmitters. Broadly speaking, these signals can either excite or inhibit neural activity.
Glutamate is the primary excitatory neurotransmitter in the brain, promoting neuronal firing and information transmission. GABA acts in opposition to glutamate by suppressing activity and preventing excessive stimulation.
A useful analogy is that of a car: glutamate is the accelerator pedal, whereas GABA is the brake. Optimal brain function requires both systems to be in balance. Too much inhibition would impair cognition and responsiveness, while too much excitation can produce instability and dysfunction.
This balance, often termed the excitatory/inhibitory (E/I) balance, appears critical for emotional regulation, cognition, learning, and stress adaptation. Emerging evidence suggests depression may involve a shift towards excessive excitation and inadequate inhibition [4].
Evidence for GABA Deficiency in Depression
Several lines of evidence support the involvement of GABA deficits in depressive disorders.
Brain imaging studies using magnetic resonance spectroscopy (MRS) have consistently shown lower GABA levels in patients with active depression compared with healthy individuals. Reductions have been observed in brain regions including the prefrontal cortex, occipital cortex, anterior cingulate cortex, and limbic structures. Meta-analyses (studies of pooled evidence) indicate that these reductions often normalize in remission, suggesting GABA abnormalities may be linked to depressive state severity rather than representing fixed traits [5,6]. Together, these findings have contributed to the "GABAergic deficit hypothesis" of depression.
Excitatory-Inhibitory Imbalance: When Neural Circuits Lose Stability
One of the most compelling theories linking GABA deficiency to depression centers on disruption of excitatory-inhibitory balance. Under normal circumstances, inhibitory interneurons regulate the firing patterns of excitatory neurons. GABAergic cells synchronize activity, filter irrelevant information, and maintain organized neural communication.
When GABA signaling decreases, excitatory activity may become relatively unchecked. Rather than a complete absence of inhibition, even subtle reductions can alter network behavior across large brain regions.
Recent systematic reviews suggest depression involves widespread changes in glutamatergic and GABAergic signaling across cortical and limbic systems, producing regional disturbances in E/I balance [4].
Several consequences may emerge from this, including hyperactivity of emotional circuits, impaired prefrontal regulation, and increased neural noise. Collectively, these alterations may contribute to hallmark depressive symptoms including rumination, impaired concentration, emotional dysregulation, and negative thinking patterns.
Stress Overload and the GABA System
Stress is among the strongest risk factors for depression, a fact consistently demonstrated in the literature [7–10]. Importantly, GABA plays a critical role in regulating the body’s stress response system, and the hypothalamic-pituitary-adrenal (HPA) axis in particular.
Under normal conditions, stress activates the HPA axis, after which cortisol levels rise; then GABAergic circuits help terminate the response and restore balance (homeostasis). GABA therefore functions partly as a biological "off switch." When GABA signaling is impaired, stress responses may become exaggerated or prolonged.
Research suggests chronic stress itself can weaken GABAergic function, creating a vicious cycle where the stress response compounds out of control, in a negative feedback loop. This cycle may contribute to chronic emotional burden and vulnerability to depression.
Chronic Stress, Glutamate, and Excitotoxicity
Reduced GABA inhibition does not merely increase neural activity; it may also amplify glutamate signaling. Because glutamate drives excitation, insufficient GABA-mediated inhibition can lead to prolonged stimulation of neural circuits. Excessive glutamatergic activity may produce synaptic dysfunction, structural remodeling, impaired plasticity, and cellular stress [11,12].
Long-term overstimulation has been associated with excitotoxic processes, where excessive activation damages neuronal integrity. Moreover, brain regions involved in depression - including the hippocampus and prefrontal cortex - appear particularly vulnerable to this.
GABA and Neuroplasticity
Healthy brains continually adapt through neuroplasticity — the capacity to reorganize connections and strengthen neural pathways [13,14]. Depression increasingly appears to be associated with impaired plasticity, rather than just altered neurotransmitter levels [15,16]. GABA participates in regulating synaptic remodeling and network flexibility, and both excessive and insufficient inhibition may impair adaptive neural change.
Cognitive Symptoms and Information Processing
Depression involves more than just the emotional components. Many individuals experience impaired concentration, slowed thinking, poor memory, and reduced executive function.
Research increasingly suggests that altered GABA-mediated signaling contributes to these symptoms [17,18]. Inhibitory interneurons synchronize oscillatory brain activity necessary for efficient cognition.
Reduced inhibitory control may disrupt attention, working memory, sensory filtering, and cognitive flexibility. Altered GABA-dependent information processing has been linked to cognitive dysfunction across depression and related psychiatric disorders [17].
This perspective may explain why many patients continue experiencing cognitive symptoms even after mood improves.
What are the Therapeutic Implications?
Recognition of GABA’s role in depression is changing treatment approaches. Traditional antidepressants primarily target monoamines such as serotonin and norepinephrine. While beneficial for many individuals, these treatments do not directly address inhibitory deficits.
More recent therapeutic approaches increasingly focus on restoring network balance. Examples include the provision of certain neuroactive compounds that positively modulate GABA-A receptors and may rapidly improve depressive symptoms. These agents appear capable of restoring inhibitory tone and stabilizing disrupted networks [19,20].
Although ketamine acts largely through glutamatergic pathways, emerging evidence suggests it may indirectly restore excitation-inhibition balance [21].
Lastly, techniques such as transcranial magnetic stimulation may alter cortical circuit activity and influence inhibitory signaling [22]. Future treatments may increasingly target depression as a network disorder rather than solely a neurotransmitter deficiency.
Conclusion
Growing evidence suggests GABA deficiency may play a substantial role in depression through multiple interconnected mechanisms. Reduced inhibitory signaling can disrupt the delicate balance between excitation and inhibition, destabilizing neural circuits involved in mood regulation, cognition, and stress adaptation.
Rather than functioning merely as a "calming neurotransmitter," or brake, GABA appears central to maintaining emotional and physiological resilience. Deficits in GABA may create a state of chronic neural overload in which emotional circuits become hyperactive, stress responses remain amplified, and adaptive plasticity declines.
The emerging GABAergic framework does not replace older serotonin theories; instead, it expands them. Therefore, depression is increasingly viewed as a systems-level disorder involving widespread circuit dysregulation. As our understanding evolves, targeting GABA-related mechanisms may open new avenues for more precise and effective interventions for depression.
References
[1] D.J. Nutt, Relationship of neurotransmitters to the symptoms of major depressive disorder, J Clin Psychiatry 69 Suppl E1 (2008) 4–7.
[2] P. Blier, Neurotransmitter Targeting in the Treatment of Depression, J. Clin. Psychiatry 74 (2013) 19–24. https://doi.org/10.4088/JCP.
[3] B. Luscher, Q. Shen, N. Sahir, The GABAergic deficit hypothesis of major depressive disorder, Mol Psychiatry 16 (2011) 383–406. https://doi.org/10.1038/mp.
[4] Y.-T. Hu, Z.-L. Tan, D. Hirjak, G. Northoff, Brain-wide changes in excitation-inhibition balance of major depressive disorder: a systematic review of topographic patterns of GABA- and glutamatergic alterations, Mol Psychiatry 28 (2023) 3257–3266. https://doi.org/10.1038/
[5] K.E.M. Godfrey, A.C. Gardner, S. Kwon, W. Chea, S.D. Muthukumaraswamy, Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis, Journal of Psychiatric Research 105 (2018) 33–44. https://doi.org/10.1016/j.
[6] B. Luscher, T. Fuchs, GABAergic Control of Depression-Related Brain States, in: Advances in Pharmacology, Elsevier, 2015: pp. 97–144. https://doi.org/10.1016/bs.
[7] R.T. Liu, L.B. Alloy, Stress generation in depression: A systematic review of the empirical literature and recommendations for future study, Clinical Psychology Review 30 (2010) 582–593. https://doi.org/10.1016/j.cpr.
[8] G. Richter-Levin, L. Xu, How could stress lead to major depressive disorder?, IBRO Reports 4 (2018) 38–43. https://doi.org/10.1016/j.
[9] C.H. Vinkers, M. Joëls, Y. Milaneschi, R.S. Kahn, B.W.J.H. Penninx, M.P.M. Boks, STRESS EXPOSURE ACROSS THE LIFE SPAN CUMULATIVELY INCREASES DEPRESSION RISK AND IS MODERATED BY NEUROTICISM: Research Article: Cumulative Stress, Neuroticism, and Depression, Depress Anxiety 31 (2014) 737–745. https://doi.org/10.1002/da.
[10] S. Hassamal, Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories, Front. Psychiatry 14 (2023) 1130989. https://doi.org/10.3389/fpsyt.
[11] M. Popoli, Z. Yan, B.S. McEwen, G. Sanacora, The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission, Nat Rev Neurosci 13 (2012) 22–37. https://doi.org/10.1038/
[12] S. Passlick, C.R. Rose, G.C. Petzold, C. Henneberger, Disruption of Glutamate Transport and Homeostasis by Acute Metabolic Stress, Front. Cell. Neurosci. 15 (2021) 637784. https://doi.org/10.3389/fncel.
[13] Defining neuroplasticity, in: Handbook of Clinical Neurology, Elsevier, 2022: pp. 3–18. https://doi.org/10.1016/B978-
[14] P. Mateos-Aparicio, A. Rodríguez-Moreno, The Impact of Studying Brain Plasticity, Front. Cell. Neurosci. 13 (2019) 66. https://doi.org/10.3389/fncel.
[15] I. Rădulescu, A. Drăgoi, S. Trifu, M. Cristea, Neuroplasticity and depression: Rewiring the brain’s networks through pharmacological therapy (Review), Exp Ther Med 22 (2021) 1131. https://doi.org/10.3892/etm.
[16] M.J. Player, J.L. Taylor, C.S. Weickert, A. Alonzo, P. Sachdev, D. Martin, P.B. Mitchell, C.K. Loo, Neuroplasticity in Depressed Individuals Compared with Healthy Controls, Neuropsychopharmacol 38 (2013) 2101–2108. https://doi.org/10.1038/npp.
[17] G. Sanacora, A. Saricicek, GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action, CNSNDDT 6 (2007) 127–140. https://doi.org/10.2174/
[18] R.S. Duman, G. Sanacora, J.H. Krystal, Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments, Neuron 102 (2019) 75–90. https://doi.org/10.1016/j.
[19] A.J. Cutler, G.W. Mattingly, V. Maletic, Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder, Transl Psychiatry 13 (2023) 228. https://doi.org/10.1038/
[20] T. Terao, H. Hirakawa, How neuroactive steroids rapidly improve depression?: GABA-GABA interaction-induced glutamatergic activation hypothesis, Medical Hypotheses (2026) 112015. https://doi.org/10.1016/j.
[21] E.D. Fagerholm, R. Leech, S. Williams, C.A. Zarate, R.J. Moran, J.R. Gilbert, Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression, Transl Psychiatry 11 (2021) 335. https://doi.org/10.1038/
[22] D.M.D. Tran, N.S. Chowdhury, N.A. McNair, J.A. Harris, E.J. Livesey, Linking cortical and behavioural inhibition: Testing the parameter specificity of a transcranial magnetic stimulation protocol, Brain Stimulation 13 (2020) 1381–1383. https://doi.org/10.1016/j.brs.
